

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

**CanSino Biologics Inc.**  
**康希諾生物股份公司**

*(A joint stock company incorporated in the People's Republic of China with limited liability)*

**(Stock code: 6185)**

**INSIDE INFORMATION**  
**CHANGE OF INTERESTS OF PARTIES ACTING IN CONCERT**

This announcement is made by the Company pursuant to Rule 13.09 of the Hong Kong Listing Rules and the Inside Information Provisions (as defined under the Hong Kong Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

**BACKGROUND**

The Concert Parties, comprising Dr. Yu, Dr. Zhu, Dr. Qiu and Dr. Mao, entered into the Concert Party Agreement on February 13, 2017, which was subsequently amended on January 26, 2022, re-entered into on March 27, 2024, amended on July 24, 2024 and further amended on December 3, 2024. Pursuant to the Concert Party Agreement, the Concert Parties have undertaken to, among other things, vote (and procure the entities held by them if any to vote) unanimously for any resolutions proposed at any general meeting of the Company.

Dr. Zhu was the sole general partner of each of the Employee Incentive Platforms. Accordingly, the Concert Parties were entitled to exercise the voting rights attached to the Shares held by the Employee Incentive Platforms.

**CHANGE OF GENERAL PARTNER OF THE EMPLOYEE INCENTIVE PLATFORMS**

On December 13, 2024, Dr. Zhu informed the Board that, in order to focus on the Company's core business development given the sufficient time required to manage the Employee Incentive Platforms, all partners of the Employee Incentive Platforms unanimously resolved to appoint Wei LI as the new general partner of Shanghai Qianxiyi and Shanghai Qianxirui, and Xiaoman DONG as the new general partner of Shanghai Qianxizhi, respectively, each being an Independent Third Party (the "**GP Change**"). Accordingly, Dr. Zhu ceased to be the general partner of the Employee Incentive Platforms and was no longer entitled to exercise the voting rights attached to the Shares held by the Employee Incentive Platforms.

## IMPACT ON THE CONCERT PARTIES

Following the GP Change, the Concert Parties' aggregate interests in the Company decreased from approximately 31.29% to approximately 28.07%. Set out below is a table showing the changes in the interests of the Concert Parties:

	Immediately before the GP Change		Immediately after the GP Change		
	<i>Number of Shares</i>	<i>Percentage of total issued Shares<sup>(3)</sup></i>	<i>Shareholders</i>	<i>Number of Shares</i>	<i>Percentage of total issued Shares<sup>(3)</sup></i>
<i>Shareholders</i>					
Dr. Yu	17,974,200	7.26%	Dr. Yu	17,974,200	7.26%
Dr. Zhu	17,984,200	7.27%	Dr. Zhu	17,984,200	7.27%
Dr. Qiu	17,114,200	6.92%	Dr. Qiu	17,114,200	6.92%
Dr. Mao <sup>(1)</sup>	16,334,200	6.60%	Dr. Mao <sup>(1)</sup>	16,334,200	6.60%
Dr. Chao <sup>(2)</sup>	50,000	0.02%	Dr. Chao <sup>(2)</sup>	50,000	0.02%
Employee Incentive Platforms	7,981,225	3.23%	–	–	–
<b>Total</b>	<b>77,438,025</b>	<b>31.29%</b>	<b>Total</b>	<b>69,456,800</b>	<b>28.07%</b>

### Notes:

- (1) Dr. Mao directly holds 9,206,828 Shares and indirectly holds 7,127,372 Shares through her wholly-owned entities, namely, CHAMPDEN LLC and Medicharms LLC.
- (2) Dr. Chao is the spouse of Dr. Mao.
- (3) The percentage figures have been subjected to rounding adjustments. Any discrepancies between the total percentage figure listed herein and respective percentage figure listed in each column are due to rounding adjustments.

As a result, the Concert Parties have ceased to be the Controlling Shareholders as they no longer control 30% or more of the voting power at general meetings of the Company, but remain as the single largest group of Shareholders.

The Company believes that the GP Change would not have any adverse impact on the Group's governance structure, shareholding structure or on-going operations.

**Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.**

## DEFINITIONS

Unless the context otherwise requires, the capitalized terms used herein shall have the following meanings:

“A Share(s)”	ordinary shares in the share capital of our Company with a nominal value of RMB1.00 each and listed on the Sci-Tech Innovation Board of the Shanghai Stock Exchange and traded in RMB
“Board” or “Board of Directors”	the board of directors of the Company
“Company”	CanSino Biologics Inc. (康希諾生物股份公司), a joint stock company incorporated in the PRC with limited liability on February 13, 2017, or, where the context requires (as the case may be), its predecessor, Tianjin CanSino Biotechnology Inc. (天津康希諾生物技術有限公司), a company incorporated in the PRC with limited liability on January 13, 2009
“Concert Parties”	Dr. Yu, Dr. Zhu, Dr. Qiu and Dr. Mao
“Concert Party Agreement”	the agreement entered into between Dr. Yu, Dr. Zhu, Dr. Qiu and Dr. Mao on February 13, 2017 which was subsequently amended on January 26, 2022, re-entered into on March 27, 2024, amended on July 24, 2024 and further amended on December 3, 2024, pursuant to which Dr. Yu, Dr. Zhu, Dr. Qiu and Dr. Mao have undertaken to, among other things, vote (and procure the entities held by them if any to vote) unanimously for any resolutions proposed at any general meeting of the Company
“Controlling Shareholder(s)”	has the meaning ascribed thereto under the Hong Kong Listing Rules
“Director(s)”	the director(s) of the Company
“Dr. Chao”	Dr. Shou Bai CHAO, executive Director, chief operating officer and deputy general manager of the Company and spouse of Dr. Mao
“Dr. Mao”	Dr. Helen Huihua MAO, executive vice-president and co-founder of the Company and spouse of Dr. Chao

“Dr. Qiu”	Dr. Dongxu QIU, deputy general manager and co-founder of the Company
“Dr. Yu”	Dr. Xuefeng YU, chairman of the Board, executive Director, chief executive officer, general manager and co-founder of the Company
“Dr. Zhu”	Dr. Tao ZHU, chief scientific officer, deputy general manager and co-founder of the Company
“Employee Incentive Platform(s)”	the employee incentive platform(s) of the Company, refers/refer to each of Shanghai Qianxiyi, Shanghai Qianxirui and Shanghai Qianxizhi
“Group”	the Company and its subsidiary(ies)
“H Share(s)”	overseas listed shares in the share capital of our Company with a nominal value of RMB1.00 each, which are subscribed for and traded in HKD and listed on the Main Board of the Hong Kong Stock Exchange
“Hong Kong”	the Hong Kong Special Administrative Region of the PRC
“Hong Kong Listing Rules”	the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited, as amended or supplemented from time to time
“Hong Kong Stock Exchange”	The Stock Exchange of Hong Kong Limited
“Independent Third Party(ies)”	individual(s) or company(ies) who or which is/are not connected person(s) of the Company as ascribed thereto under the Hong Kong Listing Rules
“Shanghai Qianxirui”	Shanghai Qianxirui Enterprise Management Partnership (Limited Partnership) (上海千希睿企業管理合夥企業(有限合夥)) (formerly known as Tianjin Qianrui Enterprise Management Partnership (Limited Partnership) (天津千睿企業管理合夥企業(有限合夥))), a limited partnership incorporated in the PRC on May 24, 2018 as an employee incentive platform of the Company

“Shanghai Qianxiyi”	Shanghai Qianxiyi Enterprise Management Partnership (Limited Partnership) (上海千希益企業管理合夥企業(有限合夥)) (formerly known as Tianjin Qianyi Enterprise Management Partnership (Limited Partnership) (天津千益企業管理合夥企業(有限合夥))), a limited partnership incorporated in the PRC on July 31, 2015 as an employee incentive platform of the Company
“Shanghai Qianxizhi”	Shanghai Qianxizhi Enterprise Management Partnership (Limited Partnership) (上海千希智企業管理合夥企業(有限合夥)) (formerly known as Tianjin Qianzhi Enterprise Management Partnership (Limited Partnership) (天津千智企業管理合夥企業(有限合夥))), a limited partnership incorporated in the PRC on May 24, 2018 as an employee incentive platform of the Company
“Share(s)”	ordinary share(s) in the share capital of the Company, with a nominal value of RMB1.00 each, comprising A Share(s) and H Share(s)
“Shareholder(s)”	holder(s) of the Share(s)
“the PRC”	the People’s Republic of China excluding, for the purpose of this announcement, Hong Kong, Macau Special Administrative Region and Taiwan

By order of the Board  
**CanSino Biologics Inc.**  
**Xuefeng YU**  
*Chairman*

Hong Kong, December 13, 2024

*As of the date of this announcement, the board of directors of the Company comprises Dr. Xuefeng YU, Dr. Shou Bai CHAO and Ms. Jing WANG as executive Directors, Mr. Chi Shing LI as a non-executive Director, and Mr. Shuifa GUI, Mr. Jianzhong LIU and Mr. Yiu Leung Andy CHEUNG as independent non-executive Directors.*